Article

Squamous cell carcinoma of the buccal mucosa: a retrospective analysis of 22 cases.

Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco School of Medicine, San Francisco, CA, USA.
Ear, nose, & throat journal (Impact Factor: 1.03). 11/2008; 87(10):582-6.
Source: PubMed

ABSTRACT We examined our institution's experience with 22 cases of previously untreated buccal squamous cell carcinoma via a retrospective chart review. Eleven of these patients had been treated with a combination of surgical excision and postoperative radiation therapy, 8 patients with surgical excision alone, and 3 patients with radiation therapy alone. The overall 3-year locoregional recurrence rate was 32% (n = 7). The 3-year survival rates were 82% after surgery plus radiation (9 of 11 patients), 63% after surgery alone (5 of 8), and 33% after radiation alone (1 of 3). Three-year T-category-specific survival rates were 100% for category T1 tumors (3 of 3 patients), 73% for T2 (8 of 11), 50% for T3 (3 of 6), and 50% for T4 (1 of 2). Although the small size of our study precluded any statistically significant conclusions, we believe that locoregional control and survival rates may be greater with surgical excision plus postoperative radiation than with treatment with either modality alone.

0 Bookmarks
 · 
48 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to analyze the patterns of failure and to determine clinical and pathologic factors predictive of recurrence and survival of patients treated for squamous cell carcinoma of the buccal mucosa at Princess Margaret Hospital. Retrospective chart review. A retrospective chart review of patients treated for buccal carcinoma between 1994 and 2004 was performed. Seventy patients with newly diagnosed and previously untreated squamous cell carcinoma of the buccal mucosa were included. Demographic, clinical, and pathological parameters were identified and correlated with outcomes. The patient cohort consisted of 33 males and 37 females. Most patients presented with early-stage local disease (T1-T2). Surgery was the primary treatment in 61 patients. Twenty-three patients were treated with postoperative radiotherapy. Median follow-up was 3.3 years. The 5-year local, regional, and overall control rates were 57.5%, 83.5%, and 50%, respectively. The 5-year overall survival rate was 69%. The 5-year disease-specific and recurrence-free survival rates were 76.4% and 46%, respectively. The only significant predictors of survival were the nodal status and extranodal extension. Carcinoma of the buccal mucosa is an aggressive disease, characterized by a high rate of locoregional failure. Transoral wide excision is an adequate treatment for early-stage lesions; however, a combined approach and an elective neck dissection should be considered in advanced lesions.
    The Laryngoscope 06/2012; 122(7):1552-7. · 2.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES: Alternative splicing (AS) is a key regulatory mechanism in the process of protein synthesis generating transcriptome and proteome diversity. In this study, we attempted to identify alternative splicing in a pair of BMSCC cancer and adjacent normal tissue using RNAseq datasets and also assessed the potential of these datasets to provide quantitative measurements for alternative splicing levels. MATERIALS AND METHODS: We performed high-throughput sequencing of buccal mucosal cancer and healthy tissue cDNA library which resulted in a transcriptome map of BMSCC cancer. RNAseq analysis was performed to assess alternative splicing complexity in cancer tissue and to search splice junction sequences that represent candidate 'new' splicing events. The splice junctions were predicted by SpliceMap software and putative assembled transcripts validated using the RT-PCR. We also analyzed the coding potential of alternative spliced candidate by HMMER. RESULTS: We detected a total of 11 novel splice junctions derived mostly from alternate 5' splice site; including two of them which contained new translation initiation sites (TISs). We have identified novel IgG pseudogene and a fusion transcript of MEMO1 and RPS9, which were further confirmed by PCR from genomic DNA. We also found novel putative long non-coding RNA (lncRNA), which is antisense to SPINK5 gene. The coding potential of these AS variants revealed that alternative splicing caused premature termination, insertion/deletion of amino acid (s) or formation of novel N-terminus. CONCLUSIONS: Differential splicing of these novel AS variants between cancer and adjacent normal tissue suggests their involvement in BMSCC cancer development and progression.
    Oral Oncology 04/2013; · 3.03 Impact Factor